Skip to main content
GMAB
NASDAQ Life Sciences

Genmab's Epcoritamab Phase 3 Trial Shows Improved PFS in DLBCL, OS Misses Significance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$31.36
Mkt Cap
$19.565B
52W Low
$17.235
52W High
$35.43
52W Position info
82% above low
Off High info
11% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

GMAB sits 82% above its 52-week low of $17.235 on light trading volume (0.2× avg).

Summary

Genmab announced topline Phase 3 results for epcoritamab in relapsed/refractory DLBCL, demonstrating improved progression-free survival, though overall survival did not reach statistical significance.


Key Events · Product Development and Regulatory · GMAB

  • Positive Progression-Free Survival (PFS)

    Epcoritamab monotherapy demonstrated a statistically significant improvement in progression-free survival (PFS) in patients with relapsed/refractory DLBCL (HR: 0.74).

  • Overall Survival (OS) Missed Significance

    The trial's overall survival (OS) endpoint did not reach statistical significance (HR: 0.96).

  • First Bispecific Monotherapy with Phase 3 PFS Benefit

    This is the first Phase 3 study to show improved PFS for a CD3xCD20 T-cell engaging bispecific monotherapy in relapsed/refractory DLBCL.

  • Regulatory Discussions Planned

    Genmab and AbbVie will engage with global regulatory authorities to discuss next steps for epcoritamab in this indication.


Analysis · GMAB · Life Sciences

Genmab announced topline Phase 3 results for epcoritamab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), demonstrating a statistically significant improvement in progression-free survival (PFS). This marks the first time a CD3xCD20 T-cell engaging bispecific monotherapy has achieved this in a Phase 3 study for this patient population, which represents a significant clinical advancement for patients with limited treatment options. However, the trial did not meet statistical significance for overall survival (OS), which is a key endpoint often scrutinized by regulatory bodies and investors. Despite the mixed outcome, the positive PFS data provides a basis for Genmab and its partner AbbVie to engage with global regulatory authorities regarding potential label expansion. Investors will closely monitor these regulatory discussions and the full data presentation at a future medical meeting to assess the drug's long-term market potential.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GMAB was trading at $31.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.6B. The 52-week trading range was $17.24 to $35.43. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GMAB - Latest Insights

GMAB
Nov 05, 2026, 11:04 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $54.17
Real-time Price: $51.14 info
Change: -$3.03 (-6%) info
Market Cap: $30.662B info
GMAB
Oct 28, 2026, 9:41 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $45.12
Real-time Price: $51.14 info
Change: +$6.02 (+13%) info
Market Cap: $30.662B info
GMAB
Oct 26, 2026, 11:08 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $44.35
Real-time Price: $51.14 info
Change: +$6.79 (+15%) info
Market Cap: $30.662B info
GMAB
Oct 26, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $45.35
Real-time Price: $51.14 info
Change: +$5.79 (+13%) info
Market Cap: $30.662B info
GMAB
Oct 23, 2026, 11:56 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $40.64
Real-time Price: $51.14 info
Change: +$10.50 (+26%) info
Market Cap: $30.662B info